Connor Clark & Lunn Investment Management Ltd. boosted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 6.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 99,871 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,458 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.29% of KalVista Pharmaceuticals worth $785,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Frazier Life Sciences Management L.P. increased its position in shares of KalVista Pharmaceuticals by 106.0% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,238,859 shares of the specialty pharmaceutical company’s stock valued at $21,895,000 after purchasing an additional 1,666,667 shares during the period. Tang Capital Management LLC increased its position in shares of KalVista Pharmaceuticals by 77.6% during the 4th quarter. Tang Capital Management LLC now owns 3,196,446 shares of the specialty pharmaceutical company’s stock valued at $21,608,000 after purchasing an additional 1,396,446 shares during the period. VR Adviser LLC acquired a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at $19,717,000. BlackRock Inc. increased its position in shares of KalVista Pharmaceuticals by 2.1% during the 3rd quarter. BlackRock Inc. now owns 1,706,148 shares of the specialty pharmaceutical company’s stock valued at $24,757,000 after purchasing an additional 34,653 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at $8,112,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday.
Insider Transactions at KalVista Pharmaceuticals
In other news, insider Paul K. Audhya sold 8,020 shares of the firm’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $10.73, for a total value of $86,054.60. Following the completion of the sale, the insider now owns 26,023 shares of the company’s stock, valued at $279,226.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Paul K. Audhya sold 8,020 shares of the firm’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $10.73, for a total value of $86,054.60. Following the completion of the sale, the insider now owns 26,023 shares of the company’s stock, valued at $279,226.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Benjamin L. Palleiko sold 13,067 shares of the firm’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $10.73, for a total value of $140,208.91. Following the completion of the sale, the chief financial officer now directly owns 95,254 shares of the company’s stock, valued at approximately $1,022,075.42. The disclosure for this sale can be found here. Insiders sold a total of 35,963 shares of company stock valued at $385,883 over the last quarter. Company insiders own 12.30% of the company’s stock.
KalVista Pharmaceuticals Stock Down 3.0 %
Shares of NASDAQ KALV opened at $10.61 on Friday. The stock has a market capitalization of $363.43 million, a price-to-earnings ratio of -3.16 and a beta of 1.05. The stock’s fifty day simple moving average is $10.00 and its 200 day simple moving average is $9.01. KalVista Pharmaceuticals, Inc. has a 52-week low of $4.12 and a 52-week high of $17.06.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last issued its earnings results on Friday, July 7th. The specialty pharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. As a group, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.03 earnings per share for the current year.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Read More
- Five stocks we like better than KalVista Pharmaceuticals
- Best Restaurant Stocks to Invest in Now
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- Insider Buying Explained: What Investors Need to Know
- How to Profit from These 3 Membership Club Stocks’ Strengths
- How to Buy Gold Stock and Invest in Gold
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report).
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
